Xiao Ling, Lyu Jiahua, Liu Xiao, Li Ke, Wang Yuan, Zhang Rongke, Chen Taiyu, Li Tao
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Radiotherapy Centre, Sichuan Cancer Hospital & Institute, Chengdu, China.
Nutr Cancer. 2021;73(10):1933-1940. doi: 10.1080/01635581.2020.1817511. Epub 2020 Oct 12.
The prognostic nutrition index (PNI) has been shown to have prognostic value for several common cancers. The study aim was to explore the clinical application value of the PNI for prognosis of patients with esophageal squamous cell carcinoma (ESCC) treated with radical chemoradiotherapy (CRT) or radiotherapy (RT).
Overall, 193 patients with ESCC who received radiotherapy with or without chemotherapy at Sichuan Cancer Hospital from March 20, 2012 to December 25, 2017 were retrospectively analyzed. Based on serum measurements before treatment, the PNI at ESCC recurrence was calculated as albumin (g/L) + 5 × total lymphocyte count. The Kaplan-Meier method and Cox proportional regression model were used to analyze the relationship between PNI and overall survival (OS).
The average PNI of 193 ESCC patients was 49.01 ± 4.68. The optimal cutoff value of PNI was 47.975, and the patients were divided into a low-PNI group (<47.975) and a high-PNI group (≥47.975). PNI was related to tumor length, T-stage and synchronous chemotherapy in ESCC patients ( < 0.05). The median OS for the entire group was 22.37 mo,. The median OS of patients in the high-PNI group and low-PNI group were 32.63 mo, and 15.4 mo, respectively, the 3-year survival rates were 47.5% and 32.2% and the 5-year survival rates were 37.7% and 16.8%, respectively, (all = 0.001). Univariate analysis showed that PNI, tumor length, T-stage and synchronous chemotherapy were related to the prognosis of ESCC patients ( < 0.05). Multivariate analysis showed that tumor length ( = 0.019), synchronous chemotherapy ( = 0.009) and PNI ( = 0.003) were independent prognostic factors affecting the prognosis of patients in ESCC treated with RT or CRT.
The calculation of PNI value is simple, reliable and repeatable and can improve the accuracy of a patient's prognosis. Confirmation of these results by a large-sample prospective study is desirable.
预后营养指数(PNI)已被证明对几种常见癌症具有预后价值。本研究旨在探讨PNI在接受根治性放化疗(CRT)或放疗(RT)的食管鳞状细胞癌(ESCC)患者预后中的临床应用价值。
回顾性分析2012年3月20日至2017年12月25日在四川省肿瘤医院接受放疗(无论是否联合化疗)的193例ESCC患者。根据治疗前的血清检测结果,将ESCC复发时的PNI计算为白蛋白(g/L)+5×总淋巴细胞计数。采用Kaplan-Meier法和Cox比例回归模型分析PNI与总生存期(OS)之间的关系。
193例ESCC患者的平均PNI为49.01±4.68。PNI的最佳截断值为47.975,患者被分为低PNI组(<47.975)和高PNI组(≥47.975)。PNI与ESCC患者的肿瘤长度、T分期和同步化疗有关(<0.05)。整个组的中位OS为22.37个月。高PNI组和低PNI组患者的中位OS分别为32.63个月和15.4个月;3年生存率分别为47.5%和32.2%;5年生存率分别为37.7%和16.8%(均P=0.001)。单因素分析显示,PNI、肿瘤长度、T分期和同步化疗与ESCC患者的预后有关(<0.05)。多因素分析显示,肿瘤长度(P=0.019)、同步化疗(P=0.009)和PNI(P=0.003)是影响接受RT或CRT治疗的ESCC患者预后的确切独立预后因素。
PNI值计算简单、可靠且可重复,可提高患者预后的准确性。希望通过大样本前瞻性研究来证实这些结果。